NY-MSCI
The Paris Agreement climate targets are increasingly out of reach as the world’s publicly listed companies will cause global temperatures to rise by 3°C, according to the latest MSCI Net-Zero Tracker .
With less than 10% of public companies aligned with a 1.5°C temperature rise threshold, the global carbon budget to limit global warming to 1.5°C will be exhausted by November 2026. This timeframe has moved forward by five months in just 90 days since the launch of the Net-Zero Tracker in July.
Henry Fernandez, Chairman and Chief Executive Officer, MSCI, comments: “The findings of the MSCI Net-Zero Tracker should dramatically increase the world’s sense of urgency to reduce greenhouse gas emissions. As the extreme weather events of 2021 have reminded us, climate change is not a ‘potential’ problem 30 or 40 years down the road. It is a clear and present danger to our way of life right now. What we do over the next half-decade — and especially at COP26 in Glasgow — could make the difference between avoiding or experiencing the worst climate impacts. We urge firm action rather than words at COP26 to divert the world from an imminent crisis and chart a path toward a sustainable future.”
Emissions set to rise by 6.7% in 2021
The rapidly shrinking timeframe is being driven by the significant rise in greenhouse gas emissions from public companies as global economic activity rebounds.
The Net-Zero Tracker, a quarterly gauge of climate change progress across a global universe of 9,300 public companies based on the MSCI All Country World Investable Market Index (ACWI IMI), finds that company emissions are set to rise by 6.7% this year.
No sector or region is safe
The Net-Zero Tracker also finds that less than half of listed companies are aligned with a 2°C temperature rise. No sector or region is aligned with the 2°C target. Even low emitting industries such as health care, information technology and financial services have outliers consuming a disproportionate share of their industry’s remaining budget.
From a regional perspective, although companies in developed economies are projected to become more carbon-efficient this century, every region is still emitting in excess. The problem is most extreme in Emerging Markets (EM) EMEA, where the implied temperature rise of listed companies is 4.8°C, followed by EM Americas and EM Asia, which are set to rise by 3.8°C and 3.4°C, respectively. To address this, companies need to cut their absolute carbon emissions by 10% a year on average. However, from 2016 to 2020, less than a quarter of the world’s publicly listed companies managed this feat.
Major gaps in disclosure of emissions — the laggards revealed
As investors and policymakers seek new levels of transparency on emissions, the latest Net-Zero Tracker shows:
- Saudi Arabian Oil Company, Gazprom PAO and Coal India Limited are the top three listed companies with the largest carbon footprint
- Shaanxi Coal Industry Company Ltd is the largest emitter to not disclose any of its greenhouse gas emissions
- GlaxoSmithKline plc, H&M Hennes & Mauritz and Électricité de France S.A. are listed in the top 10 companies that have published the most thorough emissions-reduction targets
- Gazprom PAO, A.P. Møller – Mærsk A/S and Toyota Industries Corporation reported additional scopes in the previous quarter and are now reporting all company emissions across most of the relevant categories (i.e., Scope 1, 2 and 3)
Remy Briand, Global Head of ESG and Climate at MSCI, adds: “While it is encouraging that some of the world’s largest listed companies are taking important steps by broadening their emissions reporting and setting decarbonization targets, the Net-Zero Tracker shows that major gaps still remain as many are failing to disclose this crucial information. Climate disclosures are critical for investors to help them assess the carbon intensity of companies, to model climate-related financial risk and the impact on the performance of portfolios, and to allocate capital accordingly. Without accurate disclosures, the chances of companies and investors reaching net-zero is a distant reality. We call on policymakers and financial regulators at COP26 to make climate-related disclosures based on international standards mandatory.”
About MSCI Inc.
MSCI is a leading provider of critical decision support tools and services for the global investment community. With over 50 years of expertise in research, data, and technology, we power better investment decisions by enabling clients to understand and analyze key drivers of risk and return and confidently build more effective portfolios. We create industry-leading research-enhanced solutions that clients use to gain insight into and improve transparency across the investment process.
Notes to Editors
*Gigaton is equal to a billion tons
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements relate to future events or performance and involve risks that may cause actual results or performance differ materially and you should not place undue reliance on them. Risks that could affect results or performance are in MSCI’s Annual Report on Form 10-K for the most recent fiscal year ended on December 31 that is filed with the SEC. MSCI does not undertake to update any forward-looking statements. No information herein constitutes investment advice or should be relied on as such. MSCI grants no right or license to use its products or services without an appropriate license. MSCI MAKES NO EXPRESS OR IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE OR OTHERWISE WITH RESPECT TO THE INFORMATION HEREIN AND DISCLAIMS ALL LIABILITY TO THE MAXIMUM EXTENT PERMITTED BY LAW.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211012005339/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
AdvanCell to participate in Jefferies Global Healthcare Conference in London11.11.2025 14:00:00 CET | Press release
AdvanCell, a clinical-stage radiopharmaceutical company developing innovative targeted alpha therapies for cancer, will attend theJefferies Global Healthcare ConferenceinLondon from 17 to 20 November 2025. The AdvanCell team – Andrew Adamovich (CEO),Anna Karmann (CMO), Matthew Vincent (CBO), Simon Puttick (CSO) and Dayle Hogg (COO) - will discuss the company’s clinical and corporate progress, including the encouraging Phase 1b trial results for 212Pb-ADVC001, recently presented at ESMO, as well as the upcoming Phase 2 expansion in metastatic castration-resistant (mCRPC) and metastatic hormone-sensitive prostate cancer (mHSPC), and progress on the company’s US expansion. “It’s an incredibly exciting time for AdvanCell,” said Andrew Adamovich, CEO of AdvanCell. “We are very encouraged by the promising Phase 1 data for ADVC001. We are expanding our US operations and manufacturing capabilities to support the next stage of development for our company, our lead asset and our pipeline. We loo
The Future Is Set for Tourism’s Next Era as the Inaugural TOURISE Summit Opens11.11.2025 13:51:00 CET | Press release
Nearly 8000 delegates register to attend the first TOURISE Summit being held 11-13 November140 global speakers set to take part With the bold ambition to rewrite the rules of travel, the inaugural TOURISE Summit under the patronage of His Royal Highness Prince Mohammed bin Salman bin Abdulaziz Al Saud, Crown Prince and Prime Minister was officially opened today by H.E. Ahmed Al Khateeb, Minister of Tourism of Saudi Arabia and Chairman of TOURISE. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251111716065/en/ His Excellency Ahmed Al Khateeb, Saudi Arabia's Minister of Tourism and Chairman of TOURISE, opens the inaugural TOURISE Summit in Riyadh. TOURISE ushers in a new era for global tourism, uniting ministers, delegates, and visionaries from around the world as the premier platform dedicated to shaping the future of global tourism. Taking place from November 11-13, 2025, immediately following the 50th United Nations Tourism
Riyadh Declaration on the Future of Tourism Sets 50-Year Roadmap as UN Tourism 26th General Assembly Closes in Saudi Arabia11.11.2025 13:39:00 CET | Press release
The 26th session of the UN Tourism General Assembly concluded today with the adoption of the Riyadh Declaration on the Future of Tourism, a momentous step taken by member states toward enhanced cooperation over the next 50 years. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251111034542/en/ 26th UN Tourism General Assembly The Declaration reaffirms the Kingdom’s leadership in global tourism and its position at the heart of major, industry-changing decisions, as the ground-breaking Declaration is poised to play a central role in advancing the 2030 Agenda for Sustainable Development, emphasizing sustainability, digital innovation, AI integration, and inclusive tourism economies. The Riyadh Declaration on the Future of Tourism is a shared roadmap to guide the sector’s next half-century around sustainability, inclusion and AI-powered innovation.It underscores strengthening international cooperation, resilience, and the empower
Prokarium Appoints Ibs Mahmood as Chief Executive Officer11.11.2025 13:06:00 CET | Press release
Prokarium, a clinical-stage biopharmaceutical company pioneering the field of microbial immunotherapy, today announced the appointment of Ibs Mahmood as Chief Executive Officer (CEO). Ibs succeeds Kristen Albright, who will join the Board of Directors to continue shaping Prokarium’s strategic direction. Ibs brings 25 years as a biotechnology entrepreneur having founded and led multiple life science companies through clinical development, financing and strategic transactions, raising more than $300 million for his own ventures and over $2 billion for clients. He previously co-founded and led AMO Pharma, DrugDev and Induction Healthcare, and enjoyed senior roles at IQVIA, Abingworth, Shire Pharma and Investec. Ibs read medicine at the University of Oxford. “Ibs’ appointment marks an important step in Prokarium’s evolution. His unique blend of medical insight, entrepreneurial drive and industry experience will help us accelerate our mission to change the treatment paradigm in bladder canc
FDA Approves Promega OncoMate® MSI Dx Analysis System as Companion Diagnostic for KEYTRUDA® in Combination with LENVIMA® In Advanced Endometrial Carcinoma11.11.2025 13:00:00 CET | Press release
Promega MSI technology will aid in the identification of patients with microsatellite stable (MSS) endometrial carcinoma The U.S. Food and Drug Administration (FDA) has approved the Promega OncoMate® MSI Dx Analysis System as a companion diagnostic designed to identify patients with microsatellite stable (MSS; defined as not MSI-high [not MSI-H]) endometrial carcinoma who may benefit from treatment with KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, plus LENVIMA® (lenvatinib), the orally available multiple receptor tyrosine kinase inhibitor discovered by Eisai. This is the first Promega companion diagnostic to receive FDA approval. OncoMate® MSI Dx Analysis System is a PCR-based assay designed to evaluate MSI status in tumor tissue. MSI status can be used to guide treatment decisions and support precision oncology strategies in endometrial carcinoma. “This approval underscores the critical role diagnostics play in accurately matching the right patients, at the right time with th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
